Immix Historical Income Statement

IMMX Stock

USD 1.97 0.32 19.39%

Historical analysis of Immix Biopharma income statement accounts such as Depreciation And Amortization of 3 K or Interest Expense of 0.0 can show how well Immix Biopharma performed in making a profits. Evaluating Immix Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immix Biopharma's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Immix Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immix Biopharma is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

About Immix Income Statement Analysis

Immix Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immix Biopharma shareholders. The income statement also shows Immix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Immix Biopharma Income Statement Chart

At this time, Immix Biopharma's Net Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 7.8 M in 2024, whereas Tax Provision is likely to drop slightly above 12.5 K in 2024.

Tax Provision Interest Expense Selling General Administrative Other Operating Expenses Net Income From Continuing Ops Ebit

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immix Biopharma. It is also known as Immix Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Immix Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immix Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.At this time, Immix Biopharma's Net Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 7.8 M in 2024, whereas Tax Provision is likely to drop slightly above 12.5 K in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	1.4M	8.2M	16.1M	16.9M
Cost Of Revenue	2.5K	2.1K	5.5K	3.0K

Total Operating Expenses Cost Of Revenue

Immix Biopharma income statement Correlations

	Tax Provision	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses
Tax Provision		-0.04	-0.13	0.03	-0.27	0.46	-0.21	0.19	0.73	0.19	-0.15	0.19	-0.18	-0.21	-0.53	0.7	0.7	0.71	0.95	0.17
Net Interest Income	-0.04		0.81	-0.86	0.96	-0.08	0.98	-0.97	-0.47	-0.97	0.99	-0.97	0.8	0.98	0.66	-0.52	0.27	-0.51	0.25	-0.93
Depreciation And Amortization	-0.13	0.81		-0.62	0.84	-0.06	0.83	-0.85	-0.67	-0.85	0.81	-0.85	1.0	0.83	0.89	-0.7	-0.11	-0.7	0.08	-0.65
Interest Expense	0.03	-0.86	-0.62		-0.86	0.5	-0.88	0.88	0.22	0.88	-0.89	0.88	-0.62	-0.88	-0.52	0.25	-0.51	0.25	-0.19	0.69
Selling General Administrative	-0.27	0.96	0.84	-0.86		-0.26	1.0	-1.0	-0.65	-1.0	0.99	-1.0	0.84	1.0	0.77	-0.68	0.08	-0.68	0.0	-0.88
Gross Profit	0.46	-0.08	-0.06	0.5	-0.26		-0.23	0.25	0.13	0.25	-0.21	0.25	-0.09	-0.23	-0.24	0.12	-0.07	0.12	0.49	-0.1
Other Operating Expenses	-0.21	0.98	0.83	-0.88	1.0	-0.23		-1.0	-0.59	-1.0	1.0	-1.0	0.83	1.0	0.74	-0.63	0.15	-0.63	0.07	-0.9
Operating Income	0.19	-0.97	-0.85	0.88	-1.0	0.25	-1.0		0.59	1.0	-1.0	1.0	-0.85	-1.0	-0.75	0.63	-0.14	0.63	-0.08	0.87
Net Income From Continuing Ops	0.73	-0.47	-0.67	0.22	-0.65	0.13	-0.59	0.59		0.59	-0.54	0.59	-0.69	-0.59	-0.81	1.0	0.71	1.0	0.57	0.52
Ebit	0.19	-0.97	-0.85	0.88	-1.0	0.25	-1.0	1.0	0.59		-1.0	1.0	-0.85	-1.0	-0.75	0.63	-0.14	0.63	-0.08	0.87
Research Development	-0.15	0.99	0.81	-0.89	0.99	-0.21	1.0	-1.0	-0.54	-1.0		-1.0	0.81	1.0	0.7	-0.58	0.2	-0.58	0.13	-0.9
Ebitda	0.19	-0.97	-0.85	0.88	-1.0	0.25	-1.0	1.0	0.59	1.0	-1.0		-0.85	-1.0	-0.75	0.63	-0.14	0.63	-0.08	0.87
Cost Of Revenue	-0.18	0.8	1.0	-0.62	0.84	-0.09	0.83	-0.85	-0.69	-0.85	0.81	-0.85		0.83	0.91	-0.72	-0.13	-0.72	0.03	-0.64
Total Operating Expenses	-0.21	0.98	0.83	-0.88	1.0	-0.23	1.0	-1.0	-0.59	-1.0	1.0	-1.0	0.83		0.74	-0.63	0.15	-0.63	0.07	-0.9
Reconciled Depreciation	-0.53	0.66	0.89	-0.52	0.77	-0.24	0.74	-0.75	-0.81	-0.75	0.7	-0.75	0.91	0.74		-0.82	-0.35	-0.82	-0.34	-0.58
Income Before Tax	0.7	-0.52	-0.7	0.25	-0.68	0.12	-0.63	0.63	1.0	0.63	-0.58	0.63	-0.72	-0.63	-0.82		0.68	1.0	0.53	0.56
Total Other Income Expense Net	0.7	0.27	-0.11	-0.51	0.08	-0.07	0.15	-0.14	0.71	-0.14	0.2	-0.14	-0.13	0.15	-0.35	0.68		0.68	0.74	-0.14
Net Income	0.71	-0.51	-0.7	0.25	-0.68	0.12	-0.63	0.63	1.0	0.63	-0.58	0.63	-0.72	-0.63	-0.82	1.0	0.68		0.53	0.55
Income Tax Expense	0.95	0.25	0.08	-0.19	0.0	0.49	0.07	-0.08	0.57	-0.08	0.13	-0.08	0.03	0.07	-0.34	0.53	0.74	0.53		-0.14
Selling And Marketing Expenses	0.17	-0.93	-0.65	0.69	-0.88	-0.1	-0.9	0.87	0.52	0.87	-0.9	0.87	-0.64	-0.9	-0.58	0.56	-0.14	0.55	-0.14

Click cells to compare fundamentals

Immix Biopharma Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immix Historical Income Statement

About Immix Income Statement Analysis

Immix Biopharma Income Statement Chart

Tax Provision

Interest Expense

Other Operating Expenses

Immix Biopharma income statement Correlations

Immix Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Immix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Total Operating Expenses	- 1.0	Ebitda
Ebitda	- 1.0	Research Development
Total Operating Expenses	- 1.0	Ebit
Research Development	- 1.0	Ebit
Total Operating Expenses	- 1.0	Operating Income
Research Development	- 1.0	Operating Income